Logo 1 Logo 2

Clinical Trial Details

Trial ID: L7206
Source ID: NCT00449553
Associated Drug: Pioglitazone And Sulphonylurea
Title: Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone.
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes Mellitus
Interventions: DRUG: Pioglitazone and sulphonylurea|DRUG: Pioglitazone and sulphonylurea|DRUG: Pioglitazone and metformin|DRUG: Pioglitazone and metformin
Outcome Measures: Primary: Change from baseline in glycosylated hemoglobin., 6 months | Secondary: Change from baseline in Clinical Laboratory Tests (alanine transaminase, hematocrit and hemoglobin)., End of Treatment|Change from baseline in Body Weight., End of Treatment|Percentage of treatment responders defined as a patient with 0.6% decrease in HbA1C from baseline visit to final visit or accomplishment of a HbA1c value at or below 6.5%., End of Treatment|Change from baseline in beta-cell function (Homeostasis model assessment)., End of Treatment|Change from baseline in insulin resistance (Homeostasis model assessment)., End of Treatment|Change from baseline in fasting lipoproteins (total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein-cholesterol and triglycerides)., End of Treatment
Sponsor/Collaborators: Sponsor: Takeda | Collaborators: Eli Lilly and Company
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases:
Enrollment: 326
Study Type: OBSERVATIONAL
Study Designs: Observational Model: |Time Perspective: p
Start Date: 2001-06
Completion Date: 2003-09
Results First Posted:
Last Update Posted: 2012-02-28
Locations: Multiple, Denmark|Multiple, Iceland|Multiple, Norway|Multiple, Sweden
URL: https://clinicaltrials.gov/show/NCT00449553